Aspirin for the prevention of cardiovascular morbidity

M Sanchez-Ross1, A H Waller, J Maher

  • 1University Hospital, UMDNJ, Newark, USA.

Minerva Medica
|October 30, 2010
PubMed

Insights

Aspirin (acetylsalicylic acid) use for cardiovascular event prevention shows benefits but emerging data questions its widespread primary prevention recommendations. Physicians must balance aspirin

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Aspirin (acetylsalicylic acid, ASA) is established for secondary cardiovascular (CV) event prevention.
  • Current guidelines recommend ASA for primary CV event prevention in moderate-high risk adults.
  • Emerging data challenges the efficacy and safety of these recommendations.

Purpose of the Study:

  • To review contemporary trial data on ASA efficacy and safety in various patient subsets.
  • To propose strategies for enhancing ASA's safety and efficacy in primary prevention.
  • To guide physicians in balancing CV risk reduction against bleeding risks.

Main Methods:

  • Review of recent randomized clinical trials on aspirin use.
  • Analysis of efficacy and safety data across different patient populations.
  • Synthesis of strategies for optimizing aspirin therapy.

Main Results:

  • Contemporary data presents a nuanced view on aspirin's benefits versus risks.
  • Efficacy and safety profiles vary significantly among patient subsets.
  • Bleeding complications remain a primary concern.

Conclusions:

  • Re-evaluation of aspirin's role in primary CV event prevention is warranted.
  • Personalized risk-benefit assessment is crucial before prescribing aspirin.
  • Combined strategies may enhance aspirin's therapeutic index for primary prevention.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...